
    
      This is an open-label, multi-center, single-dose, Phase 1 clinical trial designed to evaluate
      the pharmacokinetics (PK) of dexamethasone phosphate ophthalmic solution delivered via the
      EyeGateÂ® II Drug Delivery System (EGDS) in the vitreous humor taken from patients undergoing
      vitrectomy for macular hole repair or epiretinal membrane peeling
    
  